Table 5.

Cumulative genetic risk analysis of adverse genotypes in glioma cases and control subjects

No. of variant or adverse genotypesNo. of cases/controlsOR (95% CI)P for trend
The total six risk-conferring SNPs0.0004
0∼2*45/701.00 (reference)
3∼4223/2321.55 (1.00-2.35)
5∼693/552.67 (1.59-4.57)
IR exposure and the total six risk-conferring SNPs0.008
No IR and 0∼244/621.00 (reference)
No IR and 3∼6280/2691.45 (0.91-2.25)
Have IR and 0∼29/121.08 (0.40-2.97)
Have IR and 3∼624/84.28 (1.65-11.41)
  • NOTE: Adjusted for age and gender.

  • * We treat the minor allele of the two-risk-effect single-nucleotide polymorphisms and the common allele of the four-protective-effect single-nucleotide polymorphisms as the adverse allele, and set individuals with fewer than three adverse alleles as the reference group. Adverse genotypes: for four protective single-nucleotide polymorphisms, APEX1 E148D (recessive, V V), PARP A762V (dominant, V V + W V), MGMT F84L (dominant, V V + W V), and LIG1 5′UTR (dominant, V V + W V); for the two risk single-nucleotide polymorphisms, ERCC1 3′UTR (recessive, W W + W V) and XRCC1 R399Q (dominant, W W).

  • The no ionizing radiation exposure group and with fewer than three adverse genotypes defined as the reference.